A number of new agents active against small cell lung cancer are now available. Carboplatin, unlike cisplatin the parent analogue, has several advantages. Carboplatin is less emetic and is without significant nephrotoxicity, neurotoxicity or ototoxicity (Calvert et al., 1982; Smith et al., 1985; Wiltshaw, 1985) . Carboplatin has high activity as a single agent in small cell lung cancer with a response rate of 60% and 82% when used with etoposide in previously untreated patients (Smith et al., 1985 (Smith et al., , 1987 . Myelosuppression was the main toxicity but treatment was otherwise well tolerated. Ifosfamide (an isomer of cyclophosphamide) and etoposide with thoracic radiotherapy has given an overall response rate of 97% without severe toxicity, and a median survival of 11 months in limited stage patients . The actual 2-year survival (from a more recent analysis) in the above group of patients is 22%. The myelosuppressive carboplatin was therefore combined with the ifosfamide, etoposide and thoracic radiotherapy. Vincristine was also given at mid-course to help prevent relapse between chemotherapy treatments. as defined by previous multivariant analysis . In nine patients (21%) the Karnofsky performance status was good, i.e. >80, and in seven patients (17%) the score was reduced to 50 or less (Karnofsky et al., 1948) .
Patients and methods

Forty
Treatment regimen
Carboplatin was given at 300 mgm-2 as a 1 h i.v. infusion in 500ml of 5% dextrose on day 1. Etoposide was administered at 120mg m 2 i.v. on days 1 and 2 and 240mgm-2 orally on day 3. Ifosfamide 5gm2 with the same dose of mesna was given immediately after the carboplatin as a 24h, 21, N (Karnofsky et al., 1948; Medical Research Council Lung Cancer Working Party, 1979 Smith et al. (1987) . The nadir blood count was taken from weekly counts after chemotherapy. If disease progrssed the treatment protocol was discontinued and symptomatic measures were instituted. (Smith et al., 1987; Thatcher et al., 1987) . The median survival of 14 months is better than the 9.5 months and 11 months previously described with the two agent combinations in similar patient groups (Smith et al., 1987; Thatcher et al., 1987) . Furthermore, the improved median survival and actuarial 2 years survival of 37% was observed in a patient group which included pleural effusions, contralateral lymph nodes and elevated hepatic enzymes.
Myelosuppression was a serious problem and three patients died (with no evidence of tumour), probably from infection and neutropenia. However, the myelosuppression was transient and only 7% of all courses were delayed due to toxicity, and no dosage reductions were made. There was no evidence of nephrotoxicity except in one patient and treatment had to be discontinued due to renal failure following the first course. In no other patient was elevation of serum creatinine noted, and lack of nephrotoxicity compared with cisplatin was confirmed.
The incorporation of vincristine between treatment courses may have prevented the between course relapse described by Smith et al. (1987) and brain metastases may have been reduced by prophylactic cranial irradiation. Future studies using haemopoietic stimulating factors may well reduce myelosuppression and allow further development of chemotherapeutic strategies.
